These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39271992)

  • 1. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
    Elshahat A; Mansour A; Ellabban M; Diaa A; Hassan A; Fawzy A; Saad OA; Abouelmagd M; Eid M; Elaraby A; Elkasaby MH; Abdelaziz A
    BMC Cardiovasc Disord; 2024 Sep; 24(1):489. PubMed ID: 39271992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
    Hasegawa T; Nishiwaki H; Ota E; Levack WM; Noma H
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013109. PubMed ID: 33586138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure.
    Kobayashi M; Yamashina A; Satomi K; Tezuka A; Ito S; Asakura M; Kitakaze M; Ferreira JP
    Int J Cardiol; 2024 Nov; 415():132477. PubMed ID: 39181408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
    Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
    Larsson JE; Denholt CS; Thune JJ; Raja AA; Fosbøl E; Schou M; Køber L; Nielsen OW; Gustafsson F; Kristensen SL
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):546-552. PubMed ID: 37355774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world comparison of spironolactone and eplerenone in patients with heart failure.
    Pardo-Martínez P; Barge-Caballero E; Bouzas-Mosquera A; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Sagastagoitia-Fornie M; Prada-Delgado Ó; Muñiz J; Almenar-Bonet L; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Eur J Intern Med; 2022 Mar; 97():86-94. PubMed ID: 35000806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Jhund PS; Talebi A; Henderson AD; Claggett BL; Vaduganathan M; Desai AS; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Solomon SD; McMurray JJV
    Lancet; 2024 Sep; 404(10458):1119-1131. PubMed ID: 39232490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.